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First U.S. Patient Enrolls in Groundbreaking Clinical Trial at Jefferson
When James Blassingame, 79 and his wife returned home from church one Sunday, he bent down and
could not stand back up, doubled over in pain. He was rushed to a local hospital, where Joseph Lombardi,
MD, director of the new Jefferson Aortic Center and Associate Professor of Surgery was called for
consultation. Dr. Lombardi diagnosed Mr. Blassingame with a Type B dissection of his thoracic aorta.

Mr. Blassingame was transferred to the Thomas Jefferson University Hospital for surgery where he
became the first patient in the U.S. to enroll in the STABLETM Aortic Dissection clinical trial. "The STABLE
trial is an important milestone in the development of novel, minimally invasive treatments for thoracic
aortic dissections," explains Dr. Lombardi, who is global Principal Investigator (PI) of the study.

The STABLETM trial is an important milestone in the development of novel, minimally
invasive treatments for thoracic aortic dissections.
Mr. Blassingame, a retired staffing specialist for the federal government, is grandfather to 18
grandchildren and seven great grandchildren. "At my age, I was concerned about having any kind of
surgery," he recalls. "I thought I could just do without it, especially knowing that open surgery could be
fatal. But my daughter, who is a licensed nurse practitioner, explained how important and non-invasive
this surgery was, and how it would really help to reduce the risks of complications or worse." Performing
Mr. Blassingame's surgery with Dr. Lombardi was Robert A. Larson, MD, Assistant Professor of Surgery,
who serves as the site PI for the STABLETM trial. This trial and other new programs at Jefferson led to the
expansion and renaming of the Division of Vascular and Endovascular Surgery.
Endovascular surgery directs therapy through catheters and wires placed within the blood vessels. The
stents hold open the wall of the weakened vessel, and the endovascular grafts - fabric tubes used to

make a new path for the blood to flow - are placed inside the vessel. This minimally invasive method
spares patients the trauma and risk of open surgery, decreases recovery time, and improves quality of life
following the procedure.
The STABLETM trial will significantly help treat a condition that affects tens of thousands of people just
like James every year," says Dr. Lombardi. "This truly is a remarkable, lifesaving advancement."
For more information about endovascular surgery visit: www.jeffersonhospital.org/aortic

The Surgeons Speak
James Blassingame was a perfect candidate for participation in the STABLETM Aortic Dissection clinical
trial. Given the combination of his age, medical history, and what we were able to learn from our presurgical vascular mapping, we knew that we could successfully treat him with the Cook ZenithTM
Dissection Endovascular System. The technology we now have enables us to treat patients like James in
a way that radically reduces risks and decreases the recovery period.
In Mr. Blassingame's case, our three-dimensional TerRecon workstation was critical in determining if he
was anatomically sutiable for endovascular surgery. We used the 3D imaging to measrue the size of the
vessel and to determine how much to treat. It is the ultimate planning tool - enabling you to visualize the
procedure, select the right devices, and see in advance exactly where the weakened vessel begins and
ends. Once planned, the operation was performed with state of the art equipment in our new
endovascular operating suite.

--Joseph V. Lombardi, MD, and Robert A. Larson, MD
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When James Blassingame, 79, and his
wife returned home from church one
Sunday, he bent down and could not
stand back up, doubled over in pain.
He was rushed to a local hospital,
where Joseph Lombardi, MD, director
of the new Jefferson Aortic Center and
Associate Professor of Surgery was
called for consultation. Dr. Lombardi
diagnosed Mr. Blassingame with a
Type B dissection of his thoracic aorta.
Mr. Blassingame was transferred to the
Thomas Jefferson University Hospital for
surgery where he became the first patient
in the U.S. to enroll in the STABLE™
Aortic Dissection clinical trial. “The
STABLE trial is an important milestone
in the development of novel, minimally
invasive treatments for thoracic aortic
dissections,” explains Dr. Lombardi,
who is global Principal Investigator (PI)
of the study.

The STABLE™ trial is
an important milestone
in the development of
novel, minimally invasive
treatments for thoracic
aortic dissections
Mr. Blassingame, a retired staffing
specialist for the federal government,
is grandfather to 18 grandchildren and
seven great grandchildren. “At my age,
I was concerned about having any kind
of surgery,” he recalls. “I thought I could
just do without it, especially knowing
that open surgery could be fatal. But

Mr. James Blassingame, the first patient in the U.S. to enroll in the STABLE™ Aortic Dissection
clinical trial, contemplates the morning from his front porch several months after his operation.

my daughter, who is a licensed nurse
practitioner, explained how important
and non-invasive this surgery was,
and how it would really help to reduce
the risks of complications or worse.”
Performing Mr. Blassingame’s surgery
with Dr. Lombardi was Robert A.
Larson, MD, Assistant Professor of
Surgery, who serves as the site PI for
the STABLE™ trial. This trial and other
new programs at Jefferson led to the
expansion and renaming of the Division
of Vascular and Endovascular Surgery.
Endovascular surgery directs therapy
through catheters and wires placed
within the blood vessels. The stents hold
open the wall of the weakened vessel,
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and the endovascular grafts – fabric
tubes used to make a new path for the
blood to flow – are placed inside the
vessel. This minimally invasive method
spares patients the trauma and risk of
open surgery, decreases recovery time,
and improves quality of life following
the procedure.
“The STABLE™ trial will significantly
help treat a condition that affects tens of
thousands of people just like James every
year,” says Dr. Lombardi. “This truly is a
remarkable, lifesaving advancement.”
For more information about
endovascular surgery visit:
www.jeffersonhospital.org/aortic
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The Surgeons Speak

James Blassingame was a perfect
candidate for participation in the
STABLE™ Aortic Dissection clinical
trial. Given the combination of his
age, medical history, and what we
were able to learn from our pre-surgical
vascular mapping, we knew that we
could successfully treat him with the
Cook Zenith™ Dissection Endovascular
System. The technology we now have
enables us to treat patients like James
in a way that radically reduces risks and
decreases the recovery period.
In Mr. Blassingame’s case, our threedimensional TeraRecon workstation
was critical in determining if he was
anatomically suitable for endovascular
surgery. We used the 3D imaging to
measure the size of the vessel and to
determine how much to treat. It is the
ultimate planning tool—enabling you
to visualize the procedure, select the
right devices, and see in advance exactly
where the weakened vessel begins and
ends. Once planned, the operation
was performed with state of the art
equipment in our new endovascular
operating suite.
Joseph V. Lombardi, MD, (shown left)

and Robert A. Larson, MD
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